Comparative gastrointestinal safety of weekly oral bisphosphonates

Osteoporosis International

Volumn 20, Issue 10, 2009, Pages 1735-1747

  Cadarette, S M ^a,b   Katz, J N ^a   Brookhart, M A ^a   Sturmer T ^a,c   Stedman, M R ^a   Levin, R ^a   Solomon, D H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c IL   (United States)

Author keywords

Bisphosphonates; Drug evaluation; Drug safety; Osteoporosis; Population studies; Treatment

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SUCRALFATE;

AGE; AGED; ARTICLE; DRUG SAFETY; ENDOSCOPY; FEMALE; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; UPPER GASTROINTESTINAL BLEEDING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; ETIDRONIC ACID; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; OSTEOPOROSIS; PENNSYLVANIA; TREATMENT OUTCOME;

EID: 69949135799     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0871-8     Document Type: Article

References (40)

1. RS Stafford RL Drieling AL Hersh 2004 National trends in osteoporosis visits and osteoporosis treatment, 1988-2003 Arch Intern Med 164 1525 1530
2. E Lee AK Wutoh Z Xue JJ Hillman IH Zuckerman 2006 Osteoporosis management in a Medicaid population after the Women's Health Initiative study J Womens Health 15 155 161
3. JA Udell MA Fischer MA Brookhart DH Solomon NK Choudhry 2006 Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid J Bone Miner Res 21 765 771
4. SM Cadarette JN Katz MA Brookhart R Levin MR Stedman NK Choudhry DH Solomon 2008 Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004 J Rheumatol 35 319 326
5. RS Bobba K Beattie B Parkinson D Kumbhare JD Adachi 2006 Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease Drug Safety 29 1133 1152
6. FL Lanza RH Hunt ABR Thomson JM Provenza MA Blank Risedronate Endoscopy Study Group 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterol 119 631 638
7. ABR Thomson JK Marshall RH Hunt JM Provenza FL Lanza MG Royer Z Li MA Blank Risedronate Endoscopy Study Group 2002 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status J Rheumatol 29 1965 1974
8. S Kane NN Borisov D Brixner 2004 Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study Am J Manag Care 10 S216 S226
9. RG Miller M Bologness K Worley A Solis R Sheer 2004 Incidence of gastrointestinal events among bisphosphonate patients in an observational setting Am J Manag Care 10 S207 S215
10. CJ Rosen MC Hochberg SL Bonnick M [tmp] McClung P Miller S Broy R Kagan E Chen RA Petruschke DE Thompson AE de Papp Fosamax Actonel Comparison Trial Investigators 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151
11. S Bonnick KG Saag DP Kiel M [tmp] McClung M Hochberg SM Burnett A Sebba R Kagan E Chen DE Thompson AE de Papp Fosamax Actonel Comparison Trial (FACT) Investigators 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years J Clin Endocrinol Metab 91 2631 2637
12. S Epstein PD Delmas R Emkey KM Wilson V Hiltbrunner RC Schimmer 2006 Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety Maturitas 54 1 10
13. S Schneeweiss J Avorn 2005 A review of uses of health care utilization databases for epidemiologic research on therapeutics J Clin Epidemiol 58 323 337
14. DS Rainford SP Gutthann LAG Rodriguez 1996 Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan Hospital Automated Database Epidemiol 7 101 104
15. C Cattaruzzi MG Troncon L Agostinis LAG Rodriguez 1999 Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale Database J Clin Epidemiol 52 499 502
16. SO Dalton C Johansen L Mellemkjær B Nørgård HT Sørensen JH Olsen 2003 Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study Arch Intern Med 163 59 64
17. JG Donahue KA Chan SE Andrade A Beck M Boles DSM Buist VJ Carey JM Chandler GA Chase B Ettinger P Fishman M Goodman HA Guess JH Gurwitz AZ LaCroix TR Levin R Platt 2002 Gastric and duodenal safety of daily alendronate Arch Intern Med 162 936 942
18. BC Jacobson SC Somers CS Fuchs CP Kelly CA Camargo 2006 Body-mass index and symptoms of gastroesophageal reflux in women New Engl J Med 354 2340 2348
19. A Zullo C Hassan SMA Campo S Morini 2007 Bleeding peptic ulcer in the elderly: risk factors and prevention strategies Drugs Aging 24 815 828
20. LJ Tata PJ Fortun RB Hubbard L Smeeth CJ Hawkey CJP Smith HJ Whitaker CP Farrington TR Card J West 2005 Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 22 175 181
21. S Hernández-Diaz LAG Rodriguez 2000 Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990 s Arch Intern Med 160 2093 2099
22. T Yamaguchi T Sugimoto M Yamauchi Y Matsumori M Tsutsumi K Chihara 2005 Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women J Bone Miner Metab 23 36 40
23. J Weil MJS Langman P Wainwright DH Lawson M Rawlins RFA Logan TP Brown MP Vessey M Murphy DG Colin-Jones 2000 Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs Gut 46 27 31
24. K Ramakrishnan RC Salinas 2007 Peptic ulcer disease Am Fam Physician 76 1005 1012
25. M Udd P Miettinen A Palmu M Heikkinen E Janathuinen P Pasanen R Tarvainen H Mustonen R Julkunen 2007 Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study Scand J Gastroenterol 42 1395 1403
26. T Stürmer S Schneeweiss MA Brookhart KJ Rothman J Avorn RJ Glynn 2005 Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly Am J Epidemiol 161 891 898
27. T Stürmer M Joshi RJ Glynn J Avorn KJ Rothman S Schneeweiss 2006 A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods J Clin Epidemiol 59 437 447
28. RJ Glynn S Schneeweiss T Stürmer 2006 Indications for propensity scores and review of their use in pharmacoepidemiology Basic Clin Pharmacol Toxicol 98 253 259
29. S Schneeweiss 2006 Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Pharmacoepidemiol Drug Saf 15 291 303
30. C [tmp] MacLean S Newberry M Maglione M [tmp] McMahon V Ranganath M Suttorp W Mojica M Timmer A Alexander M [tmp] McNamara SB Desai A Zhou S Chen J Carter C Tringale D Valentine B Johnsen J Grossman 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213
31. R Lindsay 2007 Beyond clinical trials: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis Bone 40 S32 S35
32. JR Curtis AO Westfall JJ Allison A Freeman KG Saag 2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users Osteoporos Int 17 1268 1274
33. ANA Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216
34. AJ Carr PW Thompson C Cooper 2006 Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey Osteoporos Int 17 1638 1644
35. H Ideguchi S Ohno H Hattori Y Ishigatsubo 2007 Persistence with bisphophonate therapy including treatment courses with multiple sequential bisphosphonates in the real world Osteoporos Int 18 1421 1427
36. B Hamilton K [tmp] McCoy H Taggart 2003 Tolerability and compliance with risedronate in clinical practice Osteoporos Int 14 259 262
37. Y Moride L Abenhaim 1994 Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research J Clin Epidemiol 47 731 737
38. GS Cooper A Chak LE Lloyd PJ Yurchick DL Harper GE Rosenthal 2000 The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage Gastrointest Endosc 51 423 426
39. S Schneeweiss PS Wang J Avorn M Maclure R Levin RJ Glynn 2004 Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data J Gen Intern Med 19 444 450
40. PS Romano LL Roos JG Jollis 1993 Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives J Clin Epidemiol 46 1075 1079